UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 17, 2018
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of registrant as Specified in Its Charter)
Smedland 36
2600 Glostrup (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Item 8.01 Other Events
On September 17, 2018, Zealand Pharma A/S (the “Company”) completed the transactions contemplated by the purchase and sale agreement (the “Agreement”), dated September 6, 2018, by and among the Company, two of its wholly-owned Danish subsidiaries and Royalty Pharma Investments ICAV, an Irish Collective Asset-Management Vehicle.
The Agreement will be filed as an exhibit to the Company’s Annual Report on Form 20-F for the year ended December 31, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Zealand Pharma A/S | ||
|
|
| |
Date: September 17, 2018 | By: | /s/ Mats Blom | |
|
| Name: | Mats Blom |
|
| Title: | Chief Financial Officer |